4/6
09:19 am
trda
Rating for TRDA
Medium
Report
Rating for TRDA
4/6
09:19 am
trda
Rating for TRDA
Medium
Report
Rating for TRDA
4/1
09:00 am
trda
Entrada Therapeutics (TRDA) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.
Medium
Report
Entrada Therapeutics (TRDA) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.
4/1
06:56 am
trda
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
Medium
Report
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
4/1
06:29 am
trda
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
Medium
Report
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
2/18
08:13 am
trda
Entrada Therapeutics (NASDAQ:TRDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Entrada Therapeutics (NASDAQ:TRDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/13
06:29 am
trda
Entrada Therapeutics (NASDAQ:TRDA) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
High
Report
Entrada Therapeutics (NASDAQ:TRDA) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
2/13
06:29 am
trda
Entrada Therapeutics (NASDAQ:TRDA) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
High
Report
Entrada Therapeutics (NASDAQ:TRDA) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
2/11
09:48 am
trda
Rating for TRDA
Medium
Report
Rating for TRDA
2/11
09:48 am
trda
Rating for TRDA
Medium
Report
Rating for TRDA
2/11
06:08 am
trda
Entrada Therapeutics initiated with a Buy at Guggenheim
Low
Report
Entrada Therapeutics initiated with a Buy at Guggenheim
2/11
06:08 am
trda
Entrada Therapeutics initiated with a Buy at Guggenheim
Low
Report
Entrada Therapeutics initiated with a Buy at Guggenheim
2/10
04:19 pm
trda
Entrada Therapeutics initiated with a Buy at Guggenheim
Low
Report
Entrada Therapeutics initiated with a Buy at Guggenheim
2/10
04:19 pm
trda
Entrada Therapeutics initiated with a Buy at Guggenheim
Low
Report
Entrada Therapeutics initiated with a Buy at Guggenheim
1/28
08:00 am
trda
Entrada Therapeutics (NASDAQ:TRDA) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $21.00 price target on the stock.
Low
Report
Entrada Therapeutics (NASDAQ:TRDA) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $21.00 price target on the stock.
1/28
07:34 am
trda
Entrada Therapeutics initiated with an Outperform at Oppenheimer
Low
Report
Entrada Therapeutics initiated with an Outperform at Oppenheimer
1/28
07:34 am
trda
Entrada Therapeutics initiated with an Outperform at Oppenheimer
Low
Report
Entrada Therapeutics initiated with an Outperform at Oppenheimer